Kainos Group plc Block Admission (0963G)
November 01 2018 - 11:53AM
UK Regulatory
TIDMKNOS
RNS Number : 0963G
Kainos Group plc
01 November 2018
1 November 2018
Kainos Group plc
("Kainos" or the "Company")
Block Admission
Kainos announces that an application has been made to the
Financial Conduct Authority and the London Stock Exchange for a
total of 1,000,000 ordinary shares of 0.5 pence each (the "Shares")
to be admitted to the Official List.
The Shares are expected to be admitted to the Official List and
to trading on the London Stock Exchange on 6 November 2018.
These Shares are being reserved under a block listing and will
be issued as a result of the award of shares pursuant to the
Company's long term incentive plans, and SAYE plans, as
follows:
2015 SAYE 250,000
2015 PSP 220,000
----------
2015 CSOP 430,000
----------
POLAND 2015 60,000
----------
2015 RSS (ROI) 40,000
----------
TOTAL 1,000,000
----------
When issued, these Shares will rank pari passu with the existing
ordinary shares.
Kainos Group plc Legal Entity Identifier:
213800H2PQMIF3OVZY47
Ends
For further information, please contact:
Kainos via FTI Consulting LLP
Brendan Mooney, Chief Executive Officer
Richard McCann, Chief Financial Officer
Investec Bank plc +44 20 7597 5970
Patrick Robb / Sebastian Lawrence
Canaccord Genuity +44 20 7523 4606
Simon Bridges / Emma Gabriel
FTI Consulting LLP +44 20 3727 1000
Matt Dixon / Harry Staight
About Kainos
Kainos Group plc is a UK-based provider of Digital Services and
Digital Platforms.
The Group's Digital Services include full lifecycle development
and support of customised Digital Services for government and
commercial customers. Kainos is also the leading European partner
for Workday Inc. ('Workday') responsible for implementing Workday's
innovative Software-as-a-Service (SaaS) platform for enterprise
and, now, government customers.
The Group's Digital Platforms comprise specialised digital
products in the mobile healthcare and automated testing arenas.
Smart is an automated testing platform for Workday customers;
Evolve Electronic Medical Records ('EMR') is the market leading
product for the digitisation of patient notes in the Acute sector
of the NHS; and Evolve Integrated Care ('IC') is a SaaS-based
integrated care platform for the NHS and international healthcare
providers.
Kainos has over 1,300 people across eleven offices in Europe and
the USA, working interchangeably across its Services and Platforms
divisions.
Kainos is listed on the London Stock Exchange (LSE: KNOS). For
further information, please visit www.kainos.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ALSUASVRWBAARAA
(END) Dow Jones Newswires
November 01, 2018 11:53 ET (15:53 GMT)
Kainos (LSE:KNOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kainos (LSE:KNOS)
Historical Stock Chart
From Apr 2023 to Apr 2024
